Here are six key trends in the market:
1. The bone graft substitutes market is valued at over $21 million.
2. DePuy Synthes is the leading player in the market. The company is known for its tricalcium phosphate-based ChronOs portfolio and Norian.
3. DePuy also released the first commercial demineralized bone matrix product in the Australian market.
4. There was acceleration in the growth rate of procedures and average selling prices between 2012 and 2014, driven by the introduction and rapid commercial expansion of the DBM product.
5. Stryker is the second leading player in the market. The company is known for its tricalcium phosphate-based Vitoss and HAP-based HydroSet synthetic products.
6. Other players in the market include Zimmer Biomet, Medtronic and Wright Medical.
More articles on devices:
Dr. Nicole Ehrhart’s preclinical study affirms AlloStem Cellular Bone Allograft effectiveness: 5 key takeaways
Safe Orthopaedics names Pierre Dumouchel CEO: 3 things to know
Aurora Spine receives $1M insider loan: 4 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
